Free Trial

Sana Biotechnology (SANA) Stock Price, News & Analysis

-0.04 (-0.48%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.07 million shs
Average Volume
1.94 million shs
Market Capitalization
$1.83 billion
P/E Ratio
Dividend Yield
Price Target

Sana Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
41.2% Upside
$11.67 Price Target
Short Interest
20.85% of Float Sold Short
Dividend Strength
News Sentiment
0.84mentions of Sana Biotechnology in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.15) to ($1.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.60 out of 5 stars

Medical Sector

445th out of 920 stocks

Biological Products, Except Diagnostic Industry

63rd out of 149 stocks

SANA stock logo

About Sana Biotechnology Stock (NASDAQ:SANA)

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

SANA Stock Price History

SANA Stock News Headlines

Sana: Q1 Earnings Snapshot
Sana Biotechnology: Now In Overbought Territory
SANA Apr 2024 15.000 call
See More Headlines
Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.69 per share


Free Float
Market Cap
$1.83 billion
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

SANA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sana Biotechnology stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SANA shares.
View SANA analyst ratings
or view top-rated stocks.

What is Sana Biotechnology's stock price target for 2024?

4 Wall Street analysts have issued 1 year target prices for Sana Biotechnology's stock. Their SANA share price targets range from $8.00 to $15.00. On average, they expect the company's share price to reach $11.67 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts price targets for SANA
or view top-rated stocks among Wall Street analysts.

How have SANA shares performed in 2024?

Sana Biotechnology's stock was trading at $4.08 on January 1st, 2024. Since then, SANA stock has increased by 102.5% and is now trading at $8.26.
View the best growth stocks for 2024 here

When is Sana Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our SANA earnings forecast

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) announced its earnings results on Thursday, February, 29th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.03. During the same quarter in the prior year, the business posted ($0.40) earnings per share.

What ETFs hold Sana Biotechnology's stock?

ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Sana Biotechnology IPO?

Sana Biotechnology (SANA) raised $322 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 15,000,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.

Who are Sana Biotechnology's major shareholders?

Sana Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.51%), Baillie Gifford & Co. (4.83%), Capital World Investors (2.46%), Price T Rowe Associates Inc. MD (1.67%), Baker BROS. Advisors LP (1.07%) and Zimmer Partners LP (0.09%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang, Robert Nelsen and Ventures Fund V Gener Flagship.
View institutional ownership trends

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SANA) was last updated on 5/23/2024 by Staff

From Our Partners